Aberdeen Group
MREO

Aberdeen Group’s Mereo BioPharma MREO Stock Holding History

Aberdeen Group’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,538,699
Closed -$11.4M – 972
2025
Q3 		$11.4M Buy
5,538,699
+2,509,827
+83% +$4.63M 0.02% 587
2025
Q2 		$8.21M Buy
3,028,872
+840,518
+38% +$2.03M 0.01% 642
2025
Q1 		$4.92M Buy
+2,188,354
New +$6.19M 0.01% 681
2024
Q3 		– Sell
-73,168
Closed -$263K – 947
2024
Q2 		$263K Sell
73,168
-744,141
-91% -$2.41M ﹤0.01% 907
2024
Q1 		$2.7M Sell
817,309
-733,773
-47% -$2.48M 0.01% 746
2023
Q4 		$3.58M Buy
+1,551,082
New +$2.97M 0.01% 724

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Aberdeen Group's MREO Position: Q4 2025 in Review

Aberdeen Group sold out of Mereo BioPharma (MREO) in Q4 2025, closing a stake of 5,538,699 shares — an estimated $11.4M sold.

Aberdeen Group first reported a position in MREO in Q4 2023 and held it in 6 quarters. The position peaked at $11.4M in Q3 2025. 70 funds tracked by Wall St. Rank hold MREO as of Q4 2025.

  • Aberdeen Group reported no remaining Mereo BioPharma position as of Q4 2025 after selling out during the quarter.
  • Aberdeen Group sold 5,538,699 Mereo BioPharma shares in Q4 2025, an estimated $11.4M.
  • Aberdeen Group first reported a position in Mereo BioPharma in Q4 2023 and held it in 6 quarters.
  • Aberdeen Group's Mereo BioPharma position peaked at $11.4M in Q3 2025.
  • 70 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2025.

Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.